logo-loader
viewInstem PLC

Instem hails SEND platform as it delivers upbeat trading update

Instem said all three areas of the business - data collection, regulatory solutions and informatics – made “positive contributions” as it reported that profit margins had strengthened

keyboard with the word approved on it
The company develops and sells software that aids the regulatory submission process for drug makers

Instem PLC (LON:INS) saw its shares rise on Tuesday after the firm, which creates and sells software used by drug developers, said orders for its SEND platform grew 500% year-on-year as it told investors that 2018 trading had been in line with forecasts.

SEND stands for Standard for the Exchange of Nonclinical Data and demand for the system benefited as clients upgraded and extended their use of the company’s products.

WATCH: SEND platform the star first-half performer for Instem

Instem said all three areas of the business - data collection, regulatory solutions and informatics – made “positive contributions” as it reported profit margins had strengthened.

Customers are now shifting away from the software licence model to recurring, software-as-a-service, which aids customer retention and allows users to incrementally build the list of services it buys from the AIM-listed group.

Heavy investment pays off

"Instem has invested significantly in the business in recent years and these results further illustrate such investment converting into profitable growth,” said chief executive Phil Reason.

“In addition to a host of new client wins, many existing clients have extended their use of Instem's products and services and, importantly, have transitioned to our SaaS solutions.”

The company said it ended the year with £3.6mln, which will increase as delayed payments from a small number of large pharma customers are received.

This, Instem added, will return the company to “more normal working capital cycles”.

In the update, the company referred to an ongoing German legal dispute due in court for an initial hearing on Tuesday.

Instem said it is defending the action. It didn’t go into the details of the case, but said it does not affect its “ongoing operations”.

While it believes the action should be dismissed, a provision against the cost of litigation made in 2017 will stand in the 2018 accounts.

In early afternoon trading, Instem shares were 7.5% higher at 273p.

 -- Adds share price --

Quick facts: Instem PLC

Price: 371 GBX

AIM:INS
Market: AIM
Market Cap: £60.46 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Instem PLC named herein, including the promotion by the Company of Instem PLC in any Content on the Site, the Company receives from said issuer...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Instem PLC reports strong demand for its informatics services

Instem PLC's (LON:INS) chief scientific officer and head of its informatics arm Dr Gordon Smith Baxter tells Proactive London the value of new orders for the division has grown by 58% to £840,000. He says the firm's expansion into informatics is bringing them into contact with customers at an...

3 days, 13 hours ago

RNS

Holding(s) in Company

2 weeks, 4 days ago

Holding(s) in Company

3 weeks, 1 day ago

Half-year Report

3 weeks, 5 days ago

Notice of Results

on 13/9/19

2 min read